Sai Parenterals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals Limited has submitted a compliance filing confirming no deviations or variations in the utilization of IPO proceeds for the quarter and year ended March 31, 2026. The company raised ₹2,850 million through its IPO (Anchor: March 23, 2026; Listing: March 24–27, 2026). Funds are allocated across seven objects: capacity expansion/upgradation (₹1,107.95M), new R&D Centre (₹180.23M), repayment of outstanding borrowings (₹143.02M), working capital (₹330.00M), repayment of bridge/term loans for acquisition of Noumed Pharmaceuticals via subsidiary (₹356.41M), general corporate purposes (₹447.40M), and issue expenses (₹284.99M). Both the Audit Committee and auditors have NIL comments, indicating clean utilization as per the disclosed objects.
Positive signal for investors — the company is using IPO funds exactly as promised, with no deviations. This reinforces accountability and compliance, which is especially important given the recent March 2026 IPO and ongoing monitoring by India Ratings & Research Private Limited.